Drs. Necchi, Tawagi Discuss SunRISe-4 for MIBC

At the ESMO Congress 2024, Andrea Necchi, MD, of San Raffaele Hospital and Scientific Institute, and Karine Tawagi, MD, of University of Illinois, discuss the interim analysis of SunRISe-4, a randomized, phase 2 study on the effects of TAR-200 plus cetrelimab or cetrelimab alone as neoadjuvant therapy in patients with MIBC who are ineligible for or refuse neoadjuvant cisplatin-based chemotherapy.

With encouraging efficacy and safety data provided, the pretzel device in combination with anti-PD-1 therapy may be considered a treatment option for these patients, Dr. Necchi explains.